Trial Information

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

Sponsor: Principia Biopharma Inc.

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724